^
    Apply
    Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients (HARMONi-3) (NCT05899608)
    Phase 3
    Summit Therapeutics
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/26/2023
    Primary completion :
    12/31/2027
    Completion :
    12/31/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab)
    A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (NCT05249426)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    04/12/2022
    Primary completion :
    07/16/2024
    Completion :
    08/02/2025
    SIRPA
    |
    Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
    Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer (CALGB-40503) (NCT00601900)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/24/2008
    Primary completion :
    06/30/2014
    Completion :
    05/30/2025
    ER • PGR
    |
    ER expression
    |
    Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)
    A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors (NCT06038396)
    Phase 1/2
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    08/03/2023
    Primary completion :
    02/28/2026
    Completion :
    08/31/2026
    CLDN18
    |
    CLDN1 positive
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • ciletatug vedotin (RC118)
    Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 (HARMONi-7) (NCT06767514)
    Phase 3
    Summit Therapeutics
    Recruiting
    Last update posted :
    01/20/2025
    Initiation :
    01/01/2025
    Primary completion :
    04/01/2028
    Completion :
    06/01/2029
    PD-L1
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab)
    Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma (PRIDE) (NCT05871021)
    Phase 2
    Ludwig-Maximilians - University of Munich
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    04/10/2024
    Primary completion :
    04/10/2027
    Completion :
    07/10/2027
    MGMT
    |
    IDH wild-type
    |
    Avastin (bevacizumab)
    A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors (NCT06307925)
    Phase 1
    HC Biopharma Inc.
    Recruiting
    Last update posted :
    04/10/2024
    Initiation :
    03/27/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    PD-L1
    A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours (NCT03468426)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    04/03/2024
    Initiation :
    05/03/2018
    Primary completion :
    08/06/2024
    Completion :
    11/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    ezabenlimab (BI 754091) • BI 836880
    Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (NCT01364051)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    05/25/2011
    Primary completion :
    06/06/2019
    Completion :
    03/07/2025
    CASP3
    |
    Koselugo (selumetinib) • Recentin (cediranib)
    A Study of TAVO412 in Patients With Cancer (NCT05548634)
    Phase 1
    Tavotek Biotherapeutics
    Recruiting
    Last update posted :
    12/15/2023
    Initiation :
    05/08/2023
    Primary completion :
    06/30/2024
    Completion :
    12/01/2025
    EGFR • MET
    |
    EGFR mutation • EGFR expression • EGFR overexpression • MET overexpression • MET mutation
    |
    MP412 • TAVO412
    A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors (NCT06016062)
    Phase 1
    RemeGen Co., Ltd.
    Recruiting
    Last update posted :
    11/29/2023
    Initiation :
    09/14/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    PD-1
    |
    Aidixi (disitamab vedotin)
    BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS) (NCT04072042)
    Phase 2
    Ruijin Hospital
    Recruiting
    Last update posted :
    10/03/2023
    Initiation :
    08/31/2019
    Primary completion :
    02/25/2024
    Completion :
    05/25/2024
    KDR • CSF1R
    |
    AiTan (rivoceranib)
    AK112 in Advanced Non-Small Cell Lung Cancer (AK112-303) (NCT05499390)
    Phase 3
    Akeso
    Active, not recruiting
    Last update posted :
    09/21/2023
    Initiation :
    11/09/2022
    Primary completion :
    06/17/2024
    Completion :
    06/17/2025
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab)
    AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer (AK112-306) (NCT05840016)
    Phase 3
    Akeso
    Recruiting
    Last update posted :
    08/23/2023
    Initiation :
    08/17/2023
    Primary completion :
    12/20/2024
    Completion :
    12/20/2025
    PD-L1
    |
    PD-L1 expression
    |
    carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • Yidafan (ivonescimab)
    MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy (NCT01068587)
    Phase 1/2
    NCIC Clinical Trials Group
    Completed
    Last update posted :
    08/04/2023
    Initiation :
    01/21/2010
    Primary completion :
    03/21/2014
    Completion :
    02/13/2015
    EGFR
    |
    EGFR expression • EGFR negative
    |
    cisplatin • erlotinib • foretinib (GSK1363089)
    Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC (Endouble) (NCT05203276)
    Phase 2
    The First People's Hospital of Lianyungang
    Recruiting
    Last update posted :
    06/22/2023
    Initiation :
    03/01/2022
    Primary completion :
    05/30/2024
    Completion :
    06/30/2024
    EGFR • PD-L1 • ALK • ROS1
    |
    Enweida (envafolimab) • Endostar (recombinant human endostatin)
    Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients (NCT05846867)
    Phase 1/2
    Akeso
    Not yet recruiting
    Last update posted :
    05/08/2023
    Initiation :
    05/10/2023
    Primary completion :
    05/10/2024
    Completion :
    07/10/2025
    MLH1 • MSH6 • MSH2
    |
    PD-L1 expression • MSH6 expression
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • drebuxelimab (AK119)
    Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI) (NCT05219318)
    Phase 3
    University Hospital, Bordeaux
    Recruiting
    Last update posted :
    03/13/2023
    Initiation :
    01/23/2023
    Primary completion :
    01/01/2024
    Completion :
    01/01/2025
    PD-L1 • PD-1
    PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer (NCT04715633)
    Phase 2
    Sun Yat-sen University
    Active, not recruiting
    Last update posted :
    01/31/2023
    Initiation :
    12/01/2020
    Primary completion :
    12/30/2023
    Completion :
    12/31/2024
    MSI
    |
    MSI-H/dMMR
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • oxaliplatin
    Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer (NCT05690035)
    Phase 2
    Sun Yat-sen University
    Not yet recruiting
    Last update posted :
    01/27/2023
    Initiation :
    02/01/2023
    Primary completion :
    12/01/2023
    Completion :
    01/01/2026
    ARID1A
    |
    ARID1A mutation
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC (AK112-202) (NCT04900363)
    Phase 1/2
    Akeso
    Recruiting
    Last update posted :
    10/11/2022
    Initiation :
    05/21/2021
    Primary completion :
    05/01/2023
    Completion :
    05/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Yidafan (ivonescimab)
    Study of AK112 in the Treatment of Advanced Gynecological Tumors (AK112-203) (NCT04870177)
    Phase 2
    Akeso
    Active, not recruiting
    Last update posted :
    10/11/2022
    Initiation :
    03/16/2021
    Primary completion :
    05/01/2023
    Completion :
    05/01/2024
    PD-L1 • BRCA1 • BRCA2 • MSI
    |
    PD-L1 expression • BRCA2 mutation • BRCA1 mutation • MSI-H/dMMR
    |
    Yidafan (ivonescimab)
    First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial (FTANLCNDG) (NCT05574998)
    Phase 2
    Qianfoshan Hospital
    Recruiting
    Last update posted :
    10/11/2022
    Initiation :
    02/01/2021
    Primary completion :
    02/01/2024
    Completion :
    04/01/2024
    EGFR • ALK • ROS1
    |
    EGFR mutation
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Endostar (recombinant human endostatin)
    A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer (NCT05227664)
    Phase 2
    Akeso
    Recruiting
    Last update posted :
    09/12/2022
    Initiation :
    03/23/2022
    Primary completion :
    01/30/2023
    Completion :
    10/30/2023
    HER-2 • ER • PGR
    |
    HER-2 negative • PGR expression
    |
    albumin-bound paclitaxel • Yidafan (ivonescimab) • ligufalimab (AK117)
    A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors (NCT05229497)
    Phase 1/2
    Akeso
    Recruiting
    Last update posted :
    05/11/2022
    Initiation :
    05/04/2022
    Primary completion :
    02/01/2023
    Completion :
    02/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • 5-fluorouracil • Yidafan (ivonescimab) • ligufalimab (AK117)
    A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer (NCT04499352)
    Phase 2
    Boehringer Ingelheim
    Withdrawn
    Last update posted :
    11/15/2021
    Initiation :
    09/14/2020
    Primary completion :
    10/19/2020
    Completion :
    10/19/2020
    PD-L1 • CD4
    |
    ezabenlimab (BI 754091) • BI 836880
    PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy (NCT04942301)
    Phase 1
    Jiangsu Simcere Pharmaceutical Co., Ltd.
    Not yet recruiting
    Last update posted :
    06/30/2021
    Initiation :
    07/30/2021
    Primary completion :
    12/25/2021
    Completion :
    10/15/2022
    PD-L1
    |
    Endostar (recombinant human endostatin)
    Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC) (NCT02113800)
    Phase 2
    AIO-Studien-gGmbH
    Completed
    Last update posted :
    10/28/2020
    Initiation :
    08/01/2015
    Primary completion :
    04/01/2020
    Completion :
    04/01/2020
    CHGA
    |
    everolimus
    Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma (NCT04447326)
    Phase 2
    First Affiliated Hospital of Guangxi Medical Un...
    Not yet recruiting
    Last update posted :
    06/25/2020
    Initiation :
    06/01/2020
    Primary completion :
    06/01/2024
    Completion :
    06/01/2026
    PD-L1
    |
    Loqtorzi (toripalimab-tpzi) • Endostar (recombinant human endostatin)
    Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC (ENPOWER) (NCT04063449)
    Phase N/A
    Dong Wang
    Unknown status
    Last update posted :
    08/21/2019
    Initiation :
    08/20/2019
    Primary completion :
    06/30/2020
    Completion :
    06/30/2021
    PD-L1
    |
    carboplatin • Tyvyt (sintilimab) • Endostar (recombinant human endostatin)
    Advanced Refractory Solid Tumors With TP53 Mutations Register Study (NCT03927599)
    Phase N/A
    Tianjin Medical University Second Hospital
    Unknown status
    Last update posted :
    08/20/2019
    Initiation :
    08/01/2018
    Primary completion :
    12/31/2019
    Completion :
    01/31/2020
    TP53
    Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer (NCT03907098)
    Phase 2
    Zhejiang Cancer Hospital
    Unknown status
    Last update posted :
    04/08/2019
    Initiation :
    06/30/2016
    Primary completion :
    12/30/2019
    Completion :
    06/30/2020
    HER-2
    |
    HER-2 negative
    |
    Endostar (recombinant human endostatin)
    Rh-Endostatin (Endostar®) Continuous Intravenous Infusion (NCT03706703)
    Phase 2
    Affiliated Cancer Hospital & Institute of Guang...
    Unknown status
    Last update posted :
    10/17/2018
    Initiation :
    10/01/2018
    Primary completion :
    04/01/2020
    Completion :
    09/01/2020
    EGFR • ALK • ROS1
    |
    EGFR mutation • RET mutation
    |
    carboplatin • docetaxel • pemetrexed • Endostar (recombinant human endostatin)
    Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC (NCT03008109)
    Phase 3
    Zaiwen Fan
    Unknown status
    Last update posted :
    01/04/2017
    Initiation :
    02/01/2017
    Primary completion :
    11/01/2017
    Completion :
    11/01/2018
    EGFR
    |
    EGFR mutation
    |
    Endostar (recombinant human endostatin)
    The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients (NCT02865304)
    Phase 3
    Fujian Cancer Hospital
    Unknown status
    Last update posted :
    08/12/2016
    Initiation :
    12/01/2016
    Primary completion :
    12/01/2017
    Completion :
    12/01/2018
    HER-2
    |
    HER-2 negative
    |
    Endostar (recombinant human endostatin)
    Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma (NCT02804646)
    Phase 4
    Anhui Provincial Hospital
    Unknown status
    Last update posted :
    06/21/2016
    Initiation :
    06/01/2016
    Primary completion :
    12/01/2017
    Completion :
    12/01/2018
    EGFR
    |
    EGFR wild-type • ALK wild-type • EGFR wild-type + ALK wild-type • ALK negative
    |
    cisplatin • carboplatin • pemetrexed • Endostar (recombinant human endostatin)
    Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research (NCT02513355)
    Phase 4
    Nanjing NingQi Medicine Science and Technology ...
    Unknown status
    Last update posted :
    08/04/2015
    Initiation :
    02/01/2015
    Primary completion :
    11/01/2017
    EGFR • ALK
    |
    EGFR mutation • ALK mutation
    |
    cisplatin • paclitaxel • Endostar (recombinant human endostatin)